GlassScriptPhysician profile
Lundy Davis
NPI 1518433366
$837.42
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $196.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $124.99 | 2021 | |
| Gilead Sciences, INC. | $120.96 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $96.76 | 2021 | |
| Cvrx, INC. | $95.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $92.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $87.03 | 2022 | |
| Eisai INC. | $86.31 | 2021 | |
| Pfizer INC. | $13.71 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lundy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.